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Available online 30 July 2020Introduction: Mortality in persons living with epilepsy (PwE) is 1.6–9.3-fold higher than in the general popula-
tion. Mortality from definite/probable Sudden Unexpected Death in EPilepsy (SUDEP) is estimated at 1.2 per
1000 person-years. We report mortality and SUDEP rate in a cohort of Rwandan PwE.
Methods: PwE presenting for a first visit at the Ndera epilepsy center between January and June 2016 were
followed-up prospectively. For PwEwho did not attend their follow-up visit, home visits were organized. Deaths
were assessed using World Health Organization Verbal Autopsy Standards age-specific questionnaires.
Results:Of 235 PwE enrolled, home visits were organized for 81 (34.4%) PwEwho did not return for their follow-
up consultation. Seven fatalities (mortality 16.7/1000 patient-years [CI 6.7–34.3]) were recorded (aged 2–80
years). Four had an identified cause. Three were classified as probable SUDEP, resulting in a probable SUDEP
rate of 7.1/1000 patient-years (CI 1.47–20.86). Probable SUDEP occurred in PwE (age: 2, 21, 34 years) showing
no symptoms of illness while receiving antiepileptic treatment; in two cases, death occurred during sleep.
Conclusion: Although autopsieswere absent, the highmortality and probable SUDEP rates warrant future studies
to establish causes of epilepsy-related deaths in Rwanda and sub-Saharan Africa.






WHO Verbal Autopsy Questionnaire1. Introduction
Epilepsy is considered the most prevalent neurological condition,
andmore than 85% of persons livingwith epilepsy (PwE) live in low-in-
come and low- and middle-income countries (LLMIC) [1]. In 2016, it
was estimated that 45.9 million PwE worldwide had active epilepsy
and 70 million had lifetime epilepsy [2]. In sub-Saharan Africa (SSA),
there is an overall prevalence estimate of active epilepsy and lifetime
epilepsy of 9‰ and 16‰, respectively, with modest variation from oneKigali; CI, confidence interval;
and low- and middle-income
aharan Africa; SUDEP, sudden
eizure; WHO, World Health
echelsestraat 24, B-2500 Lier,
Dedeken),
be (P.A.J.M. Boon).
. This is an open access article undersubregion to another [3]. Prevalence is twice as high in rural areas as it
is in urban settings [3].
Epilepsy is a global public health issue and results – for those af-
fected and their families – in medical, developmental, psychosocial,
and economic consequences, which in turn are an important cause of
epilepsy-associated poverty. In LLMICs, this increases not only the bur-
den of disease with high numbers of years lived with disability but
also years of life lost because of premature mortality [4].
Premature death in PwE in SSA poses an additional challenge.
Worldwide, age-standardized mortality rates of epilepsy from un-
known or genetic cause were calculated at 1.74 per 100,000 people
(specifically, 1.40 for women and 2.09 for men) [2]. PwE living in SSA
have the highest standardized mortality ratio, with a median of 5.4
(range 2.6–7.2) [5].
The incidence of Sudden Unexpected Death in EPilepsy (SUDEP) is
important [6,7]. In high-income countries, the incidence of definite
and/or probable SUDEP among PwE is 1.2 per 1000 person-years (95%
CI 0.9–1.5; range 1.1 in PwE <16 years to 1.3 in adults >50 years ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clear. Definite SUDEP is consideredwhen diagnostic criteria aremet and
when no other cause of death has been identified through an autopsy or
immediate observation surveillance. As autopsies in SSA are very rarely
performed, SUDEP is often only reported as probable or possible.
In this report, we describe all-cause mortality and probable SUDEP
cases prospectively studied in a cohort of PwE in Rwanda, using the
age-specific World Health Organization (WHO) Verbal Autopsy Ques-
tionnaire. This tool was designed and validated to assess cause(s) of
mortality in the absence of autopsies, which is frequent in LLMIC. The
structured questionnaire guides the interviewer during the visit, cover-
ing different causes of death and allows additional data from death
certificates at town halls or medical files, if available [9].2. Materials and methods
Between January and June 2016, PwE presenting at the CARAESNeu-
ropsychiatric tertiary hospital (CARAES-NPH) at Ndera (Kigali, Rwanda)
were enrolled into an ambispective cohort study only if they presented
at the clinic for the first time and had a first seizure or an epilepsy diag-
nosis of <12 months. Epilepsy was defined as a history of two or more
unprovoked seizures [10]. Survival status was assessed by a physical
presentation at an out-patient consultation. If a PwE had not returned
(lost for follow-up), a homevisit was organized to assess the PwEhealth
status.
A multidisciplinary team, including a neurologist, nurse, and
research assistant, visited PwE and family at their last known ad-
dress. Upon verbal consent, the survey, approved by the Ethical Re-
view Board of the CARAES-NPH and Institutional Review Board of
the University Teaching Hospital – Kigali (CHU-K), was adminis-
tered. Survival status verification was completed at 19 months after
the enrollment.
When family members reported the death of a PwE, another home
visit was conducted. The team interviewed family and/or caregivers
using the age-specific World Health Organization (WHO) Verbal Au-
topsy Questionnaire age-specific questionnaire [9].2.1. Classification of epilepsy-related deaths
We used the 2016 classification of epilepsy-related deaths with four
categories: (i) deaths due directly to epilepsy, including SUDEP; (ii)
deaths due indirectly to epilepsy; (iii) deaths due to acute symptomatic
seizures; and, (iv) deaths due to underlying disease [7].2.2. Criteria and classification of SUDEP
The SUDEP criteria used were: (i) the deceased, before death, had to
have had repetitive unprovoked epileptic seizures; (ii) death had to
have occurred unexpectedly, i.e., in an everyday situation and in people
with an otherwise unremarkable state of health; (iii) death had to have
occurred suddenly, i.e., within minutes (if observed); and (iv) there had
to be no evidence of any other cause of death, e.g., trauma, drowning,
status epilepticus, burns, or accident [11,12].
Six categories of SUDEP were considered: (i) definite SUDEP if di-
agnostic criteria were met without evidence of another cause of
death through an autopsy or immediate observation surveillance;
(ii) probable SUDEP if any or all of the criteria described above
were met in the absence of an autopsy; (iii) possible SUDEP if a com-
peting cause of death was present; (iv) near-SUDEP when a PwE had
a resuscitation after a respiratory and cardiovascular arrest for which
no other cause was found, with the person surviving for up to 1 h; (v)
no SUDEP if a clear cause of deathwas known; and, (vi) unclassifiable
SUDEP when incomplete information did not allow classification
[11,12].3. Results
A total of 235 PwE were followed up prospectively. Based on the
medical records, at 19 months after inclusion, attempts to PwE by
phone were made and included 81 (34.5%) PwE who did not return
for a follow-up consultation. Of these 81 PwE, seven PwE had moved
abroad and 74 home visits were organized. Seven PwE could not be
traced at their last known address and authorities did not know their
new address. The team completed home visits of these PwE and family
members of seven deceased PwE.
Out of 35 reasons for loss to follow-up,most frequently reasons cited
were lack of insurance/financial means (25.7%), seizure cessation
(25.7%), lack of improvement (25.7%) and lack of information/having
a normal EEG (14.3%).
At study enrollment, 56% of 235 PwE were male and 70% were <20
years of age (mean 15.6 years, range 0–78 years). Focal-onset including
focal to bilateral tonic–clonic seizures (TCS) were present in 12.6% of
PwE, whereas unclassified seizures had occurred in 6%. Another 79.4%
presented with TCS with unknown onset (and may have included gen-
eralized and focal onset seizures), because of limited electroencephalo-
gram and a monthly seizure frequency >10 was reported in 19.6%.
Mean age at first seizure and at clinical diagnosis was 10.8 years and
13.4 years, respectively [13].
Clinical features and details of the seven death cases are described in
Tables 1 and 2. At baseline, five of seven deaths recorded were male
(71.4%), mean age was 31.4 years (range 1–78 years), and six of seven
(85.7%) had unknown onset TCS. Three PwE had more than 10 seizures
per month, and two had less than two seizures per month.
Based on a total of 420.3 person-years in our cohort, mortality was
16.7 per 1000 person-years (CI 6.7–34.3) conservatively excluding
seven PwE who could not be contacted and assumed alive. Four deaths
were attributed to specific causes: brain tumor, metastatic liver cancer,
head trauma secondary to a seizure, and hypovolemic shock. Of six PwE
with known time of first seizure, four had an epilepsy duration of less
than five years.
Three cases on AED treatment were classified as probable SUDEP in
the absence of trauma or concurrent illness at time of death. The SUDEP
rate in this cohort was estimated to be 7.1 per 1000 person-years (CI
1.5–20.9). At the last documented consultation, two of three PwE who
had probable SUDEP were seizure-free for 3 months after respectively
presenting with between two and five seizures and >10 seizures per
month initially. In two SUDEP cases, death occurred during sleep.
4. Discussion
This study reported all-causes mortality and SUDEP rates of a se-
lected PwE population seen at a tertiary referral center [5,6]. Mortality
in our cohort was lower than that reported in data from Kenya showing
a mortality of 33 per 1000 person-years [14]. In countries with a large
epilepsy diagnosis and treatment gap (DTG), epilepsy has an increased
incidence of premature mortality [15]. The DTGmay increase mortality
fromall causes, including deaths attributable to lack of access tomedical
facilities for diagnosis and treatment, e.g., status epilepticus, or prevent-
able causes, e.g., accidents, drowning, head traumas, and burns [15]. In
our cohort, the treatment gap may have contributed to mortality as
only one death case was on dual treatment and only two PwE were re-
ported seizure-free. Moreover, death registries are often lacking and au-
topsies not performed; hence, accurate estimation of the occurrence of
epilepsy-related mortality in LLMIC can be significantly hampered [16].
The multidisciplinary team proactively organized home visits and
interviewed family members and/or caregivers using the validated
WHO Verbal Autopsy Questionnaire to understand cause(s) of death,
to mitigate for the lack of death or epilepsy registries [9,16].
According to the 2016 classification, four deaths (57.1%) were con-
sidered directly attributable to epilepsy (three instances of probable
SUDEP and one secondary to head trauma following a seizure); two
Table 1
Demographics and seizure details of PwE with reported death.
Patient Gender Age (years) Seizure Seizure frequency Technical
investigations
Medication







EEG CT/MRI AED Concomitant
1 Male 38 40 41.0 Unknown onset,
tonic–clonic seizures
<2/mo <2/mo Partial seizure
control
Normal No Carbamazepine None
2 Female 10 30 31.4 Unknown onset,
tonic–clonic seizures
10–30/mo <2/mo Partial seizure
control
Abnormala No Valproic acid,
phenobarbital
None




Seizure-free Unknown No Carbamazepine Haloperidol
4 Male 36 36 37.1 Focal to bilateral
seizures
<2/mo <2/mo Unknown Normal Brain
tumor
Valproic acid Amitriptyline
5 Female 0 1 2.3 Unknown onset,
tonic–clonic seizures
10–30/mo 10–30/mo Partial seizure
control
Abnormalb No Valproic acid None
6 Male UNK 78 80.1 Unknown onset,
tonic–clonic seizures
5–10/mo 5–10/mo Partial seizure
control
Unknown Unknown Phenobarbital Unknown
7 Male 0 2 2.9 Focal to bilateral
seizures
10–30/mo 10–30/mo Seizure-free Abnormalc No Valproic acid None
AED= antiepileptic drug; CT/MRI= brain computed tomography/magnetic resonance imaging; DoB=date of birth; EEG= electroencephalogram; OPD=outpatient department; UNK,
unknown.
a Excess delta/theta waves, without epileptic activities.
b Theta waves.
c Severe encephalopathy.
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(14.3%) was related indirectly to epilepsy [5,7,11,12].
The proportion of probable SUDEP of 3/7 (43%) was higher than in
the Kenyan cohort (about 7%), which may be due to population differ-
ences or to the home visits we conducted [14]. The diagnosis of SUDEP
remains difficult in high-income countries and is even more complex
and unlikely to be recorded in LLMIC. Risk factors for SUDEP include
TCS, high frequency of seizures, nocturnal seizures, polytherapy, non-
compliance, age <45 years, and long duration of the condition [17]. InTable 2
Narrative and suspected causes of death in seven PwE by using the WHO Verbal Autopsy.
Patient Health status Description
1 Active life The person was apparently fine, reading at home. At around
03:00 pm, he went outside, had a seizure, fell on some steps, and
suffered head trauma. He went to bed, but was later discovered
unconscious by family members.
2 Active life At around 03:00 am, the person called out to her mother
explaining that she did not feel well. She displayed no signs of
fever, pain, or other illness. Having returned to bed to sleep, she
passed away during the night.
3 Active life At around 03:00 pm, while conducting business, the person told
his business partner that he did not feel well. He displayed no
signs of fever, pain, depression, paranoid schizophrenia, or other
illness. He went home to rest, but after 1 h, his business partner
discovered him dead at his home, without apparent injuries.
4 Deteriorating
health
The person, previously diagnosed with a brain tumor, was
admitted to the emergency department of CHU-K in a comatose




The medical history of the girl included recurrent infections,
requiring nasogastric tube feeding, and supportive care. At time
of death, the patient was again admitted with diarrhea, unable to
take oral rehydration. She died of a hypovolemic shock despite
rehydration with intra-venous fluid.
6 Deteriorating
health
The person had known lung cancer. His health status
deteriorated steadily with a severe cough, chest and abdominal




The boy with known perinatal asphyxia was apparently fine and
did not have seizures at the time of his death. He showed no signs
of any illness. At around 11:00 am, he was unable to eat and
stopped breathing soon afterwards. No convulsions were
observed by household members.
CHU-K = University Teaching Hospital – Kigali; GI = gastrointestinal disease; PwE = person
Organization.our cohort, the SUDEP risk factors of age <45 years and TCS were pres-
ent in all cases, and two PwE had a time since seizure onset ofmore than
nine years. In children, brain lesions, male gender, and cognitive or de-
velopmental delay are considered additional risk factors [5]. A delayed
mental development was observed in the two toddler SUDEP cases.
Having gathered data on mortality and SUDEP cases, the reported
rates need to be interpreted with caution as the study (i) was not
specifically designed as a mortality study; (ii) had a relatively short





Awake No No No No Head trauma,
secondary to
seizure
Asleep No No No No Probable SUDEP
Asleep No No No No Probable SUDEP
Coma No No No No Brain tumor










Awake No No No No Probable SUDEP
with epilepsy; SUDEP = Sudden Unexplained Death in Epilepsy; WHO = World Health
4 F. Sebera et al. / Epilepsy & Behavior Reports 14 (2020) 100383likely more severe epilepsy having been referred by district hospital
levels. This may have resulted in an overestimation of actual rates
compared to the general PwE population as only recently diagnosed
PwE were recruited at the tertiary reference center. Similar to other
LLMIC, further limitations to assess causes of mortality including
SUDEP were an absence of autopsies and limited access to neuroim-
aging, most likely underestimating brain lesion-related epilepsy
[14].
Given these limitations, theWHOVerbal Autopsy Questionnairewas
a useful tool for assessing the cause of mortality in a structured and sys-
tematic way. We recommend its future use in all instances of deaths of
PwE.
Research is ongoing and more is required to improve our under-
standing of both epilepsy-related mortality and SUDEP rate in Rwanda,
and to a broader extent, in SSA.
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